Close Menu

Synthetic Biology

The method can be used with isothermal amplification and paper-based readouts to detect infectious disease drug resistance in low-resource areas.

The DNA synthesis company priced shares of common stock at $28 and increased the expected proceeds from its stock offering to $130 million.

The offering of common stock will be the second for Twist this year and the third since the company made its initial public offering in October 2018.

On a conference call to discuss the firm's fiscal Q1 financial results, Twist executives detailed the firm's vision for near- and long-term growth.

A hearing scheduled for Friday, part of a lawsuit filed by Agilent was cancelled, leading to speculation the sides were close to a settlement.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.